Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Javelin reports results from phase III efficacy study of Dyloject in postsurgical pain

Dec. 15, 2008

ITI presents development update of ITI-111 for acute repetitive seizure in epilepsy

Dec. 15, 2008

Abstral receives marketing approval in Germany for breakthrough cancer pain

Dec. 12, 2008

Perampanel well tolerated in phase II study in patients with refractory partial seizures

Dec. 12, 2008

Olanzapine long-acting injection approved in Europe for schizophrenia

Dec. 12, 2008

Preliminary phase II data suggest APD-125 did not meet trial endpoints

Dec. 12, 2008

AcelRx reports results from phase II clinical study of sufentanil in postoperative pain

Dec. 12, 2008

Phosphagenics presents phase I clinical results for transdermal lidocaine

Dec. 12, 2008

Sosei reports positive results from two phase I trials of SD-118 for neuropathic pain

Dec. 11, 2008

New therapeutic agents for AD and other neurological disorders reported in recent patents

Dec. 11, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026